Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Allogene announces publication of preclinical study on DLL3, AlloCAR T » 08:37
01/25/23
01/25
08:37
01/25/23
08:37
ALLO

Allogene Therapeutics

$7.96 /

+1.105 (+16.12%)

Allogene Therapeutics…

Allogene Therapeutics announced the publication of a preclinical study demonstrating delta-like ligand 3, DLL3, is a promising tumor target for AlloCAR T in small cell lung cancer, SCLC. The findings were published in Clinical Cancer Research, a journal of the American Association for Cancer Research, AACR. This study describes the selection of ALLO-213 as an allogeneic CAR T development candidate targeting DLL3 from a large number of single chain variable fragment (scFv)-based anti-DLL3 CAR candidates. The selection of ALLO-213 was based on potency and specificity against SCLC cell lines in vitro and in vivo, including cell lines with very low antigen density to establish sensitivity. The results from the pre-clinical study showed: No DLL3 on target toxicity was observed in preclinical models supporting a potentially attractive safety profile; Clinical DLL3 CAR candidates controlled DLL3+ tumor growth in mice without normal tissue toxicity

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$7.96 /

+1.105 (+16.12%)

ALLO Allogene Therapeutics
$7.96 /

+1.105 (+16.12%)

01/24/23 JPMorgan
Allogene Therapeutics upgraded to Overweight from Neutral at JPMorgan
01/06/23 Baird
Baird upgrades 'differentiated story' Allogene Therapeutics to Outperform
01/06/23 Baird
Allogene Therapeutics upgraded to Outperform from Neutral at Baird
01/04/23 EF Hutton
Allogene Therapeutics initiated with a Buy at EF Hutton
ALLO Allogene Therapeutics
$7.96 /

+1.105 (+16.12%)

ALLO Allogene Therapeutics
$7.96 /

+1.105 (+16.12%)

Tuesday
Hot Stocks
Allogene Therapeutics announces publication of Phase 1 UNIVERSAL study data » 08:34
01/24/23
01/24
08:34
01/24/23
08:34
ALLO

Allogene Therapeutics

$6.86 /

+0.295 (+4.50%)

Allogene Therapeutics…

Allogene Therapeutics announced that data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory multiple myeloma has been published in Nature Medicine. "UNIVERSAL is the first and only allogeneic CAR T study to demonstrate that significant responses can be achieved with a single dose in patients with relapsed/refractory multiple myeloma. These initial study results published in Nature Medicine reinforce our belief that ALLO-715 can induce deep, clinically meaningful responses in patients with an allogeneic cell therapy. AlloCAR T product candidates may be able to meaningfully reduce the barriers faced by patients with multiple myeloma when seeking to access cell therapy," said David Chang, CEO. The Phase 1 UNIVERSAL study is a dose escalation trial in patients with heavily pretreated r/r MM. The Nature Medicine publication includes data from the first 48 patients enrolled with a data cutoff of October 2021. All patients treated were refractory to their last line of treatment and no bridging therapy was used in this trial. Data demonstrated the ability for an allogeneic CAR T to achieve response rates in line with certain approved autologous CAR T therapies and durable remissions with a manageable safety profile while treating 92% of all enrolled patients and all product manufactured and released as per product specifications. Updated data from the UNIVERSAL study were presented at the Company's R&D Showcase in November 2022 and the American Society of Hematology Annual Meeting in December 2022.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$6.86 /

+0.295 (+4.50%)

ALLO Allogene Therapeutics
$6.86 /

+0.295 (+4.50%)

01/24/23 JPMorgan
Allogene Therapeutics upgraded to Overweight from Neutral at JPMorgan
01/06/23 Baird
Baird upgrades 'differentiated story' Allogene Therapeutics to Outperform
01/06/23 Baird
Allogene Therapeutics upgraded to Outperform from Neutral at Baird
01/04/23 EF Hutton
Allogene Therapeutics initiated with a Buy at EF Hutton
ALLO Allogene Therapeutics
$6.86 /

+0.295 (+4.50%)

ALLO Allogene Therapeutics
$6.86 /

+0.295 (+4.50%)

Upgrade
Allogene Therapeutics upgraded to Overweight from Neutral at JPMorgan » 04:44
01/24/23
01/24
04:44
01/24/23
04:44
ALLO

Allogene Therapeutics

$6.86 /

+0.295 (+4.50%)

JPMorgan analyst Brian…

JPMorgan analyst Brian Cheng upgraded Allogene Therapeutics to Overweight from Neutral with a price target of $11, down from $20, after meeting with management. The upgrade is a "valuation call," driven by upside from current share levels, the analyst tells investors in a research note. The firm sees a "healthy strategic shift brewing behind-the- scenes" at Allogene to place a heavier focus on its lead CD19 franchise. Allogene's CD19 ALLO-501 program is still a commercially viable product with a competitive profile compared to other auto CAR-Ts in the late-line setting in diffuse large B cell lymphoma, the firm contends.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$6.86 /

+0.295 (+4.50%)

ALLO Allogene Therapeutics
$6.86 /

+0.295 (+4.50%)

01/06/23 Baird
Baird upgrades 'differentiated story' Allogene Therapeutics to Outperform
01/06/23 Baird
Allogene Therapeutics upgraded to Outperform from Neutral at Baird
01/04/23 EF Hutton
Allogene Therapeutics initiated with a Buy at EF Hutton
12/12/22 BofA
Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
ALLO Allogene Therapeutics
$6.86 /

+0.295 (+4.50%)

ALLO Allogene Therapeutics
$6.86 /

+0.295 (+4.50%)

Over a week ago
Upgrade
Baird upgrades 'differentiated story' Allogene Therapeutics to Outperform » 06:40
01/06/23
01/06
06:40
01/06/23
06:40
ALLO

Allogene Therapeutics

$5.82 /

+0.025 (+0.43%)

Baird analyst Jack Allen…

Baird analyst Jack Allen upgraded Allogene Therapeutics to Outperform from Neutral with an unchanged price target of $12. The analyst views the stock's current valuation as an attractive opportunity to gain exposure to a "differentiated story" in the allogeneic cell therapy space. Allogene's positive durability results appear differentiated, Allen tells investors in a research note. The analyst sees room for shares to "reserve their downward trend and grind higher in the coming quarters as appreciation for the durability of Allogene's approach grows."

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$5.82 /

+0.025 (+0.43%)

ALLO Allogene Therapeutics
$5.82 /

+0.025 (+0.43%)

01/06/23 Baird
Allogene Therapeutics upgraded to Outperform from Neutral at Baird
01/04/23 EF Hutton
Allogene Therapeutics initiated with a Buy at EF Hutton
12/12/22 BofA
Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
12/12/22 BofA
Allogene Therapeutics downgraded to Underperform from Buy at BofA
ALLO Allogene Therapeutics
$5.82 /

+0.025 (+0.43%)

ALLO Allogene Therapeutics
$5.82 /

+0.025 (+0.43%)

Upgrade
Allogene Therapeutics upgraded to Outperform from Neutral at Baird » 04:56
01/06/23
01/06
04:56
01/06/23
04:56
ALLO

Allogene Therapeutics

$5.82 /

+0.025 (+0.43%)

Baird analyst Jack Allen…

Baird analyst Jack Allen upgraded Allogene Therapeutics to Outperform from Neutral with an unchanged price target of $12.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$5.82 /

+0.025 (+0.43%)

ALLO Allogene Therapeutics
$5.82 /

+0.025 (+0.43%)

01/04/23 EF Hutton
Allogene Therapeutics initiated with a Buy at EF Hutton
12/12/22 BofA
Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
12/12/22 BofA
Allogene Therapeutics downgraded to Underperform from Buy at BofA
11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
ALLO Allogene Therapeutics
$5.82 /

+0.025 (+0.43%)

ALLO Allogene Therapeutics
$5.82 /

+0.025 (+0.43%)

Initiation
Allogene Therapeutics initiated with a Buy at EF Hutton » 16:11
01/04/23
01/04
16:11
01/04/23
16:11
ALLO

Allogene Therapeutics

$5.79 /

+0.04 (+0.70%)

EF Hutton analyst Tony…

EF Hutton analyst Tony Butler initiated coverage of Allogene Therapeutics with a Buy rating and $15 price target. Allogene is focused on developing off-the-shelf, allogeneic T-cell product candidates against hematological malignancies and solid tumors, Butler tells investors in a research note. The analyst says the company has developed a highly competent cell manufacturing facility that, at scale, can deliver 20,000 potential doses per year.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$5.79 /

+0.04 (+0.70%)

ALLO Allogene Therapeutics
$5.79 /

+0.04 (+0.70%)

12/12/22 BofA
Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
12/12/22 BofA
Allogene Therapeutics downgraded to Underperform from Buy at BofA
11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
ALLO Allogene Therapeutics
$5.79 /

+0.04 (+0.70%)

ALLO Allogene Therapeutics
$5.79 /

+0.04 (+0.70%)

Hot Stocks
Zai Lab appoinst Amado as President, Head of Global Oncology R&D » 08:37
01/03/23
01/03
08:37
01/03/23
08:37
ZLAB

Zai Lab

$30.69 /

-0.37 (-1.19%)

, ALLO

Allogene Therapeutics

$6.29 /

+0.33 (+5.54%)

Zai Lab (ZLAB) announced…

Zai Lab (ZLAB) announced the appointment of Rafael Amado, M.D. as President, Head of Global Oncology Research and Development, R&D, effective December 30, 2022. Dr. Amado will report to Dr. Du and will be a key member of the Company's executive committee. He will be responsible for leading and overseeing the Company's global oncology research and development activities. Dr. Amado joins Zai Lab from Allogene Therapeutics (ALLO), where he has served as Executive Vice President, Head of Research and Development and Chief Medical Officer since September 2019.

ShowHide Related Items >><<
ZLAB Zai Lab
$30.69 /

-0.37 (-1.19%)

ALLO Allogene Therapeutics
$6.29 /

+0.33 (+5.54%)

ZLAB Zai Lab
$30.69 /

-0.37 (-1.19%)

11/11/22 Citi
Zai Lab price target lowered to $127 from $199 at Citi
08/09/22 Citi
Zai Lab price target raised to $199 from $193 at Citi
05/12/22 Citi
Zai Lab price target lowered to $193 from $198 at Citi
03/17/22 Citi
Citi opens '90-day positive Catalyst Watch' on Zai Lab
ALLO Allogene Therapeutics
$6.29 /

+0.33 (+5.54%)

12/12/22 BofA
Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
12/12/22 BofA
Allogene Therapeutics downgraded to Underperform from Buy at BofA
11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
ZLAB Zai Lab
$30.69 /

-0.37 (-1.19%)

ALLO Allogene Therapeutics
$6.29 /

+0.33 (+5.54%)

ZLAB Zai Lab
$30.69 /

-0.37 (-1.19%)

ZLAB Zai Lab
$30.69 /

-0.37 (-1.19%)

ALLO Allogene Therapeutics
$6.29 /

+0.33 (+5.54%)

Hot Stocks
Allogene Therapeutics appoints Zachary Roberts as EVP, research and development » 08:09
01/03/23
01/03
08:09
01/03/23
08:09
ALLO

Allogene Therapeutics

$6.29 /

+0.33 (+5.54%)

Allogene Therapeutics…

Allogene Therapeutics announced the appointment of Zachary Roberts M.D., Ph.D. to Executive Vice President of Research and Development. The hiring of Dr. Roberts, who previously held clinical leadership roles at Instil Bio and Kite Pharma, underscores the Company's commitment to rapidly advancing its pipeline following recent clinical data illustrating the potential of its AlloCAR T product candidates to induce deep and durable responses. Dr. Roberts will assume the responsibilities of Rafael Amado, M.D. who has resigned to pursue other opportunities. Arun Balakumaran, M.D., Chief Medical Officer and Barbra Sasu, Ph.D., Chief Scientific Officer will report to Dr. Roberts.

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$6.29 /

+0.33 (+5.54%)

ALLO Allogene Therapeutics
$6.29 /

+0.33 (+5.54%)

12/12/22 BofA
Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
12/12/22 BofA
Allogene Therapeutics downgraded to Underperform from Buy at BofA
11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
ALLO Allogene Therapeutics
$6.29 /

+0.33 (+5.54%)

ALLO Allogene Therapeutics
$6.29 /

+0.33 (+5.54%)

Over a month ago
Conference/Events
Cantor biotech/biopharma analysts hold an analyst/industry conference call » 12:25
12/14/22
12/14
12:25
12/14/22
12:25
NVS

Novartis

$93.01 /

+1.755 (+1.92%)

, GILD

Gilead

$88.54 /

+0.51 (+0.58%)

, BMY

Bristol-Myers

$77.34 /

-0.01 (-0.01%)

, JNJ

Johnson & Johnson

$180.44 /

+1.07 (+0.60%)

, GRCL

Gracell

$2.57 /

+0.105 (+4.26%)

, PSTX

Poseida Therapeutics

$5.97 /

+0.385 (+6.89%)

, PGEN

Precigen

$1.70 /

+0.05 (+3.04%)

, MBIO

Mustang Bio

/

+

, ACLX

Arcellx

$32.78 /

+1.25 (+3.96%)

, ALLO

Allogene Therapeutics

$7.87 /

-0.125 (-1.56%)

, FATE

Fate Therapeutics

$15.92 /

-0.46 (-2.81%)

, HARP

Harpoon Therapeutics

/

+

Biopharma/Biotech…

Biopharma/Biotech Analysts Chen & Kim and Biotech Analyst Kluska, along with KOL speakers Dr. Dahiya, Asssoc Prof at University of Maryland and Dr. Ruella, Asst Prof at University of Pennsylvania discuss how next-generation CAR-T therapies could expand the market opportunity for these companies' treatments, including NVS, GILD, BMY, JNJ, GRCL, PSTX, PGEN, MBIO, ACLX, ALLO, FATE and HARP on an Analyst/Industry conference call to be held on December 14 at 1 pm. Webcast Link

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$5.97 /

+0.385 (+6.89%)

PGEN Precigen
$1.70 /

+0.05 (+3.04%)

NVS Novartis
$93.01 /

+1.755 (+1.92%)

MBIO Mustang Bio
/

+

JNJ Johnson & Johnson
$180.44 /

+1.07 (+0.60%)

HARP Harpoon Therapeutics
/

+

GRCL Gracell
$2.57 /

+0.105 (+4.26%)

GILD Gilead
$88.54 /

+0.51 (+0.58%)

FATE Fate Therapeutics
$15.92 /

-0.46 (-2.81%)

BMY Bristol-Myers
$77.34 /

-0.01 (-0.01%)

ALLO Allogene Therapeutics
$7.87 /

-0.125 (-1.56%)

ACLX Arcellx
$32.78 /

+1.25 (+3.96%)

NVS Novartis
$93.01 /

+1.755 (+1.92%)

12/05/22 Stifel
Novartis upgraded to Buy from Hold at Stifel
10/26/22 JPMorgan
Novartis price target lowered to CHF 78 from CHF 81 at JPMorgan
10/14/22 Barclays
Novartis price target lowered to CHF 75 from CHF 85 at Barclays
10/07/22 Deutsche Bank
Novartis price target lowered to CHF 70 from CHF 75 at Deutsche Bank
GILD Gilead
$88.54 /

+0.51 (+0.58%)

12/13/22 BofA
Gilead resumed with a Neutral at BofA
12/12/22 Needham
Arcellx price target raised to $35 from $31 at Needham
12/09/22 Piper Sandler
Gilead price target raised to $104 from $96 at Piper Sandler
12/09/22 DZ Bank
Gilead downgraded to Hold from Buy at DZ Bank
BMY Bristol-Myers
$77.34 /

-0.01 (-0.01%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
JNJ Johnson & Johnson
$180.44 /

+1.07 (+0.60%)

12/12/22 Citi
Johnson & Johnson price target raised to $205 from $198 at Citi
12/07/22 Piper Sandler
Horizon Therapeutics price target raised to $110 from $90 at Piper Sandler
12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
12/01/22 Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
GRCL Gracell
$2.57 /

+0.105 (+4.26%)

12/08/22 H.C. Wainwright
Gracell initiated with a Buy at H.C. Wainwright
09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
PSTX Poseida Therapeutics
$5.97 /

+0.385 (+6.89%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PGEN Precigen
$1.70 /

+0.05 (+3.04%)

11/18/22 Cantor Fitzgerald
Precigen initiated with an Overweight at Cantor Fitzgerald
11/18/22 Cantor Fitzgerald
Precigen initiated with an Overweight at Cantor Fitzgerald
08/09/22 H.C. Wainwright
Precigen price target lowered to $6 from $10 at H.C. Wainwright
07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
ACLX Arcellx
$32.78 /

+1.25 (+3.96%)

12/13/22 BofA
Arcellx resumed with a Buy at BofA
12/12/22 Canaccord
Arcellx price target raised to $34 from $32 at Canaccord
12/12/22 Barclays
Arcellx price target raised to $38 from $25 at Barclays
ALLO Allogene Therapeutics
$7.87 /

-0.125 (-1.56%)

12/12/22 BofA
Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
12/12/22 BofA
Allogene Therapeutics downgraded to Underperform from Buy at BofA
11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
FATE Fate Therapeutics
$15.92 /

-0.46 (-2.81%)

12/13/22 Truist
Fate Therapeutics price target lowered to $46 from $51 at Truist
12/12/22 Oppenheimer
Fate Therapeutics price target lowered to $65 from $90 at Oppenheimer
11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
HARP Harpoon Therapeutics
/

+

12/14/22 Truist
Harpoon Therapeutics downgraded to Hold from Buy at Truist
11/15/22 Baird
Harpoon Therapeutics downgraded to Neutral from Outperform at Baird
08/29/22 Citi
Harpoon Therapeutics price target lowered to $6 from $7 at Citi
08/23/22 Truist
Harpoon Therapeutics price target lowered to $7 from $12 at Truist
PSTX Poseida Therapeutics
$5.97 /

+0.385 (+6.89%)

PGEN Precigen
$1.70 /

+0.05 (+3.04%)

NVS Novartis
$93.01 /

+1.755 (+1.92%)

MBIO Mustang Bio
/

+

JNJ Johnson & Johnson
$180.44 /

+1.07 (+0.60%)

HARP Harpoon Therapeutics
/

+

GRCL Gracell
$2.57 /

+0.105 (+4.26%)

GILD Gilead
$88.54 /

+0.51 (+0.58%)

FATE Fate Therapeutics
$15.92 /

-0.46 (-2.81%)

BMY Bristol-Myers
$77.34 /

-0.01 (-0.01%)

ALLO Allogene Therapeutics
$7.87 /

-0.125 (-1.56%)

ACLX Arcellx
$32.78 /

+1.25 (+3.96%)

  • 04
    Aug
  • 17
    Jun
  • 04
    Feb
NVS Novartis
$93.01 /

+1.755 (+1.92%)

JNJ Johnson & Johnson
$180.44 /

+1.07 (+0.60%)

BMY Bristol-Myers
$77.34 /

-0.01 (-0.01%)

NVS Novartis
$93.01 /

+1.755 (+1.92%)

JNJ Johnson & Johnson
$180.44 /

+1.07 (+0.60%)

HARP Harpoon Therapeutics
/

+

GRCL Gracell
$2.57 /

+0.105 (+4.26%)

GILD Gilead
$88.54 /

+0.51 (+0.58%)

FATE Fate Therapeutics
$15.92 /

-0.46 (-2.81%)

BMY Bristol-Myers
$77.34 /

-0.01 (-0.01%)

ALLO Allogene Therapeutics
$7.87 /

-0.125 (-1.56%)

ACLX Arcellx
$32.78 /

+1.25 (+3.96%)

NVS Novartis
$93.01 /

+1.755 (+1.92%)

JNJ Johnson & Johnson
$180.44 /

+1.07 (+0.60%)

GILD Gilead
$88.54 /

+0.51 (+0.58%)

BMY Bristol-Myers
$77.34 /

-0.01 (-0.01%)

ACLX Arcellx
$32.78 /

+1.25 (+3.96%)

Conference/Events
Cantor biotech/biopharma analysts hold an analyst/industry conference call » 04:55
12/14/22
12/14
04:55
12/14/22
04:55
NVS

Novartis

$91.26 /

+0.385 (+0.42%)

, GILD

Gilead

$88.03 /

+0.21 (+0.24%)

, BMY

Bristol-Myers

$77.35 /

-1.54 (-1.95%)

, JNJ

Johnson & Johnson

$179.27 /

+1.45 (+0.82%)

, GRCL

Gracell

$2.47 /

+0.105 (+4.45%)

, PSTX

Poseida Therapeutics

$5.57 /

+0.05 (+0.91%)

, PGEN

Precigen

$1.65 /

+0.025 (+1.54%)

, MBIO

Mustang Bio

/

+

, ACLX

Arcellx

$31.53 /

+3.03 (+10.63%)

, ALLO

Allogene Therapeutics

$8.00 /

-0.05 (-0.62%)

, FATE

Fate Therapeutics

$16.38 /

+0.14 (+0.86%)

, HARP

Harpoon Therapeutics

/

+

Biopharma/Biotech…

Biopharma/Biotech Analysts Chen & Kim and Biotech Analyst Kluska, along with KOL speakers Dr. Dahiya, Asssoc Prof at University of Maryland and Dr. Ruella, Asst Prof at University of Pennsylvania discuss how next-generation CAR-T therapies could expand the market opportunity for these companies' treatments, including NVS, GILD, BMY, JNJ, GRCL, PSTX, PGEN, MBIO, ACLX, ALLO, FATE and HARP on an Analyst/Industry conference call to be held on December 14 at 1 pm. Webcast Link

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$5.57 /

+0.05 (+0.91%)

PGEN Precigen
$1.65 /

+0.025 (+1.54%)

NVS Novartis
$91.26 /

+0.385 (+0.42%)

MBIO Mustang Bio
/

+

JNJ Johnson & Johnson
$179.27 /

+1.45 (+0.82%)

HARP Harpoon Therapeutics
/

+

GRCL Gracell
$2.47 /

+0.105 (+4.45%)

GILD Gilead
$88.03 /

+0.21 (+0.24%)

FATE Fate Therapeutics
$16.38 /

+0.14 (+0.86%)

BMY Bristol-Myers
$77.35 /

-1.54 (-1.95%)

ALLO Allogene Therapeutics
$8.00 /

-0.05 (-0.62%)

ACLX Arcellx
$31.53 /

+3.03 (+10.63%)

NVS Novartis
$91.26 /

+0.385 (+0.42%)

12/05/22 Stifel
Novartis upgraded to Buy from Hold at Stifel
10/26/22 JPMorgan
Novartis price target lowered to CHF 78 from CHF 81 at JPMorgan
10/14/22 Barclays
Novartis price target lowered to CHF 75 from CHF 85 at Barclays
10/07/22 Deutsche Bank
Novartis price target lowered to CHF 70 from CHF 75 at Deutsche Bank
GILD Gilead
$88.03 /

+0.21 (+0.24%)

12/13/22 BofA
Gilead resumed with a Neutral at BofA
12/12/22 Needham
Arcellx price target raised to $35 from $31 at Needham
12/09/22 Piper Sandler
Gilead price target raised to $104 from $96 at Piper Sandler
12/09/22 DZ Bank
Gilead downgraded to Hold from Buy at DZ Bank
BMY Bristol-Myers
$77.35 /

-1.54 (-1.95%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
JNJ Johnson & Johnson
$179.27 /

+1.45 (+0.82%)

12/12/22 Citi
Johnson & Johnson price target raised to $205 from $198 at Citi
12/07/22 Piper Sandler
Horizon Therapeutics price target raised to $110 from $90 at Piper Sandler
12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
12/01/22 Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
GRCL Gracell
$2.47 /

+0.105 (+4.45%)

12/08/22 H.C. Wainwright
Gracell initiated with a Buy at H.C. Wainwright
09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
PSTX Poseida Therapeutics
$5.57 /

+0.05 (+0.91%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PGEN Precigen
$1.65 /

+0.025 (+1.54%)

11/18/22 Cantor Fitzgerald
Precigen initiated with an Overweight at Cantor Fitzgerald
11/18/22 Cantor Fitzgerald
Precigen initiated with an Overweight at Cantor Fitzgerald
08/09/22 H.C. Wainwright
Precigen price target lowered to $6 from $10 at H.C. Wainwright
07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
ACLX Arcellx
$31.53 /

+3.03 (+10.63%)

12/13/22 BofA
Arcellx resumed with a Buy at BofA
12/12/22 Canaccord
Arcellx price target raised to $34 from $32 at Canaccord
12/12/22 Barclays
Arcellx price target raised to $38 from $25 at Barclays
ALLO Allogene Therapeutics
$8.00 /

-0.05 (-0.62%)

12/12/22 BofA
Allogene cut to Underperform at BofA on decreased competitiveness of ALLO-715
12/12/22 BofA
Allogene Therapeutics downgraded to Underperform from Buy at BofA
11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
FATE Fate Therapeutics
$16.38 /

+0.14 (+0.86%)

12/13/22 Truist
Fate Therapeutics price target lowered to $46 from $51 at Truist
12/12/22 Oppenheimer
Fate Therapeutics price target lowered to $65 from $90 at Oppenheimer
11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
HARP Harpoon Therapeutics
/

+

11/15/22 Baird
Harpoon Therapeutics downgraded to Neutral from Outperform at Baird
08/29/22 Citi
Harpoon Therapeutics price target lowered to $6 from $7 at Citi
08/23/22 Truist
Harpoon Therapeutics price target lowered to $7 from $12 at Truist
08/15/22 H.C. Wainwright
Harpoon Therapeutics price target lowered to $7 from $18 at H.C. Wainwright
PSTX Poseida Therapeutics
$5.57 /

+0.05 (+0.91%)

PGEN Precigen
$1.65 /

+0.025 (+1.54%)

NVS Novartis
$91.26 /

+0.385 (+0.42%)

MBIO Mustang Bio
/

+

JNJ Johnson & Johnson
$179.27 /

+1.45 (+0.82%)

HARP Harpoon Therapeutics
/

+

GRCL Gracell
$2.47 /

+0.105 (+4.45%)

GILD Gilead
$88.03 /

+0.21 (+0.24%)

FATE Fate Therapeutics
$16.38 /

+0.14 (+0.86%)

BMY Bristol-Myers
$77.35 /

-1.54 (-1.95%)

ALLO Allogene Therapeutics
$8.00 /

-0.05 (-0.62%)

ACLX Arcellx
$31.53 /

+3.03 (+10.63%)

  • 04
    Aug
  • 17
    Jun
  • 04
    Feb
NVS Novartis
$91.26 /

+0.385 (+0.42%)

JNJ Johnson & Johnson
$179.27 /

+1.45 (+0.82%)

BMY Bristol-Myers
$77.35 /

-1.54 (-1.95%)

NVS Novartis
$91.26 /

+0.385 (+0.42%)

JNJ Johnson & Johnson
$179.27 /

+1.45 (+0.82%)

GRCL Gracell
$2.47 /

+0.105 (+4.45%)

GILD Gilead
$88.03 /

+0.21 (+0.24%)

FATE Fate Therapeutics
$16.38 /

+0.14 (+0.86%)

BMY Bristol-Myers
$77.35 /

-1.54 (-1.95%)

ALLO Allogene Therapeutics
$8.00 /

-0.05 (-0.62%)

ACLX Arcellx
$31.53 /

+3.03 (+10.63%)

NVS Novartis
$91.26 /

+0.385 (+0.42%)

JNJ Johnson & Johnson
$179.27 /

+1.45 (+0.82%)

GILD Gilead
$88.03 /

+0.21 (+0.24%)

BMY Bristol-Myers
$77.35 /

-1.54 (-1.95%)

ACLX Arcellx
$31.53 /

+3.03 (+10.63%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.